Moneycontrol PRO
HomeNewsBusinessStartek examining acquisition targets for inorganic play

Startek examining acquisition targets for inorganic play

Startek is now looking to expand its footprint in other verticals such as healthcare, where it can have a larger play.

November 18, 2020 / 19:07 IST
Representative image

Representative image

Global business process outsourcing firm Startek, which merged with Indian BPO firm Aegis two years ago, is now evaluating acquisition targets while also looking to grow its healthcare and tech support verticals, President Rajiv Ahuja told Moneycontrol.

Startek, which has been struggling with profitability over the last few years, does not seem to have turned its fortunes around since the merger with Aegis, though it did turn in a small profit in the latest quarter.

But Ahuja is looking ahead and charting out the company's plans for growth.

“Like every other company we keep our eyes and ears open for an asset that we feel could be a credit and could add value to the current asset that we have,” he said.

“So yes, we continue to examine quite a few prospects. As we speak we are doing that. It is a question of finding the right asset at the right price. Growing inorganically is not something we are ruling out. We are open to that idea,” he added.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

However, he did not disclose details about the nature of the acquisitions the company is examining or the value. According to an earlier report by the Economic Times, the company was looking at digital acquisitions to accelerate growth after the tough merger with Aegis.

Startek-Aegis merger

Indian business process management firm Aegis merged with New York Stock Exchange-listed Startek in 2018. Revenues of the combined entity then were close to $700 million, with Lance Rosenzweig as its CEO.

Profitability of the firm has been a concern. The ET report quoting David Koning, an analyst with brokerage firm RW Baird, said the company has lacked profits since 2016 and has heavy client concentration which poses a risk.

In January 2020, Aparup Sengupta, former CEO of Aegis from 2005-12, was named the Global CEO. Ahuja , a former Aegis executive, was brought in from July 2019 to integrate and lead the company to the next level of growth.

September 2020 results

For the quarter ending September 2020, the company posted a net profit of $0.4 million, as against a net loss of  $2.8 million in the year-ago quarter. For the quarter ending June 2020, the company reported a net loss of $5.2 million.

Startek’s revenue dipped 1.15 percent to $162.7 million for its third quarter ending September 2020. The decline, the company said, was on account of depreciation of the Indian rupee and the Argentine peso, and also due to the continued impact of the pandemic-induced lockdown.

Argentina accounts for about 6 percent of the company's revenues, while India contributes 13 percent.

Expanding its vertical footprint

After the contraction in demand witnessed on the back of Covid-19, it is bouncing back led by e-commerce and food delivery in India and healthcare in the US.

The company is now looking to expand its footprint in other verticals such as healthcare, where it can have a larger play. “Healthcare would be one where I think there is a tremendous amount of volume. It is a segment that we have not tapped into and we have not realised its full potential,"Ahuja said.

Tech support would be another vertical of focus, where the sales team is now trying to make more inroads, he added.

Currently, telecom accounts for about 35 percent of its revenue, followed by e-commerce and consumer at 16 percent. Healthcare and education account for about 7 percent, and technology and ITeS make up 3 percent.

Close to 51 percent of the company’s revenue comes from the top 10 clients. Though Ahuja did not respond directly to whether this high client concentration poses a risk, he said the company is looking to grow other verticals. The company has over 280 clients.

Hiring

As demand picks up, the company is also stepping up its global workforce. The company employs over 40,000 people of which 18,500 are in India,  according to a report.

The company added two senior resources in the sales team recently, one in the US and one in the UK and is in the process of examining a few more senior level resources. “We are absolutely focused. We do want to be a growth company. If we are a growth company you need to have sales people knocking on doors,” Ahuja said.

Swathi Moorthy
first published: Nov 18, 2020 07:07 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347